IRWD Ironwood Pharmaceuticals, Inc. Stock Quote

Your browser is no longer supported. Please, upgrade your browser.

publish chart | save to portfolio | create alert

IRWD [NASD]

Ironwood Pharmaceuticals, Inc.

Healthcare | Drug Manufacturers - Specialty & Generic | USA

statements

Index	-	P/E	15.65	EPS (ttm)	0.62	Insider Own	1.70%	Shs Outstand	159.41M	Perf Week	-7.04%
Market Cap	1.52B	Forward P/E	8.78	EPS next Y	1.10	Insider Trans	-2.57%	Shs Float	155.33M	Perf Month	1.90%
Income	97.10M	PEG	-	EPS next Q	0.15	Inst Own	-	Short Float	13.26%	Perf Quarter	-0.72%
Sales	426.80M	P/S	3.56	EPS this Y	129.70%	Inst Trans	1.11%	Short Ratio	10.17	Perf Half Y	-5.81%
Book/sh	-0.23	P/B	-	EPS next Y	99.64%	ROA	24.50%	Target Price	10.50	Perf Year	6.52%
Cash/sh	-	P/C	-	EPS next 5Y	-	ROE	-109.40%	52W Range	7.99 - 14.10	Perf YTD	-27.57%
Dividend	-	P/FCF	12.82	EPS past 5Y	17.80%	ROI	28.30%	52W High	-31.63%	Beta	1.50
Dividend %	-	Quick Ratio	14.00	Sales past 5Y	41.20%	Gross Margin	96.80%	52W Low	20.65%	ATR	0.50
Employees	317	Current Ratio	14.00	Sales Q/Q	-12.50%	Oper. Margin	30.50%	RSI (14)	47.44	Volatility	5.98% 5.69%
Optionable	Yes	Debt/Eq	-	EPS Q/Q	100.00%	Profit Margin	22.70%	Rel Volume	0.75	Prev Close	9.49
Shortable	Yes	LT Debt/Eq	-	Earnings	Nov 05 AMC	Payout	0.00%	Avg Volume	2.03M	Price	9.64
Recom	2.80	SMA20	-0.82%	SMA50	-2.66%	SMA200	-8.17%	Volume	1,529,141	Change	1.58%

Sep-30-20

Downgrade

Wells Fargo

Overweight → Equal Weight

$14 → $9

Jun-17-20

Initiated

Northland Capital

Outperform

$14

Jul-10-19

Resumed

Credit Suisse

Neutral

Mar-27-19

Upgrade

Morgan Stanley

Underweight → Equal-Weight

Feb-25-19

Upgrade

H.C. Wainwright

Sell → Neutral

$14

Jan-24-19

Upgrade

JP Morgan

Underweight → Neutral

Nov-07-18

Downgrade

JP Morgan

Neutral → Underweight

Nov-07-18

Downgrade

Credit Suisse

Outperform → Neutral

Jul-23-18

Initiated

H.C. Wainwright

Sell

$12.50

May-09-18

Downgrade

Morgan Stanley

Equal-Weight → Underweight

Jan-05-18

Downgrade

BofA/Merrill

Buy → Underperform

Dec-06-17

Downgrade

Mizuho

Buy → Neutral

$16

Jul-21-17

Downgrade

JP Morgan

Overweight → Neutral

May-03-17

Initiated

Wells Fargo

Outperform

Apr-07-17

Reiterated

Mizuho

Buy

$21 → $22

Feb-22-17

Reiterated

Barclays

Equal Weight

$13 → $16

Nov-04-16

Reiterated

Mizuho

Buy

$19 → $20

Oct-24-16

Reiterated

Wedbush

Neutral

$10 → $13

Oct-10-16

Reiterated

Mizuho

Buy

$24 → $19

Sep-27-16

Reiterated

WallachBeth

Hold

$15 → $17

Oct-22-20 04:01PM	Ironwood Pharmaceuticals to Host Third Quarter 2020 Investor Update Call Business Wire
12:33PM	Ironwood Pharmaceuticals (IRWD) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release Zacks
Sep-30-20 11:08AM	Ironwood to End IW-3718 Development After Study Failure Zacks
Sep-29-20 08:55AM	Ironwood Sinks 11% After Gastro Disease Treatment Study Halt SmarterAnalyst
07:15AM	Ironwood to Discontinue IW-3718 Development Program Following Results from Planned Efficacy Assessment Business Wire
Sep-27-20 07:33AM	3 Great Stocks Under $10 Motley Fool
Sep-14-20 10:55PM	Hedge Funds Getting More Bullish On Ironwood Pharmaceuticals, Inc. (IRWD) Insider Monkey
Sep-05-20 11:31AM	Why Is Ironwood (IRWD) Down 3.1% Since Last Earnings Report? Zacks
Sep-02-20 04:00PM	Ironwood Pharmaceuticals to Participate in Upcoming September Investor Conferences Business Wire
Aug-26-20 12:20PM	Surging Earnings Estimates Signal Upside for Ironwood (IRWD) Stock Zacks
Aug-07-20 02:52PM	Ironwood Pharmaceuticals'(NASDAQ:IRWD) Share Price Is Down 32% Over The Past Three Years. Simply Wall St.
11:18AM	Ironwood (IRWD) Q2 Earnings Beat on Solid Linzess Sales Zacks
Aug-06-20 10:45AM	Ironwood Pharmaceuticals (IRWD) Beats Q2 Earnings and Revenue Estimates Zacks
07:00AM	Ironwood Pharmaceuticals Reports Second Quarter 2020 Results; Delivered GAAP Net Income of $25 Million and Adjusted EBITDA of $33 Million Business Wire
Jul-30-20 12:33PM	Ironwood Pharmaceuticals (IRWD) Reports Next Week: What You Should Expect Zacks
Jul-23-20 04:05PM	Ironwood Pharmaceuticals to Host Second Quarter 2020 Investor Update Call Business Wire
12:17PM	3 Growth Stocks May Present Value Opportunities GuruFocus.com
Jul-21-20 07:00AM	Ironwood Announces Updates Designed to Strengthen IW-3718 Phase III Program for Refractory Gastroesophageal Reflux Disease (GERD) Business Wire -6.98%
Jul-12-20 07:40PM	Did Hedge Funds Make The Right Call On Ironwood Pharmaceuticals, Inc. (IRWD) ? Insider Monkey
Jun-08-20 02:51AM	Hedge Funds Still Bullish On Ironwood Pharmaceuticals, Inc. (IRWD) Insider Monkey
Jun-05-20 11:31AM	Why Is Ironwood (IRWD) Down 3.6% Since Last Earnings Report? Zacks
Jun-03-20 09:56AM	Biotech Stock Roundup: GILD's Coronavirus Drug Update, NTLA-REGN Deal & More Zacks
09:04AM	Ironwood Pharmaceuticals (IRWD) Looks Good: Stock Adds 7.6% in Session Zacks
08:32AM	Edited Transcript of IRWD earnings conference call or presentation 6-May-20 8:30pm GMT Thomson Reuters StreetEvents
May-28-20 09:10AM	Ironwood to Halt MD-7246 Development After Study Failure Zacks -8.40%
May-27-20 08:51AM	AbbVie, Ironwood to discontinue experimental IBS drug MarketWatch -8.97%
08:00AM	Ironwood and AbbVie Report Top-line Phase II Data for MD-7246 in Patients with Abdominal Pain Associated with Irritable Bowel Syndrome with Diarrhea (IBS-D) Business Wire
May-11-20 06:53AM	H.C. Wainwright Sticks to Their Hold Rating for Ironwood Pharma Investing.com +5.59%
May-07-20 10:00PM	Ironwood Pharmaceuticals Inc (IRWD) Q1 2020 Earnings Call Transcript Motley Fool
10:56AM	Ironwood (IRWD) Misses Q1 Earnings and Revenue Estimates Zacks
May-06-20 07:15PM	Ironwood Pharmaceuticals (IRWD) Misses Q1 Earnings and Revenue Estimates Zacks
04:05PM	Ironwood Pharmaceuticals Reports First Quarter 2020 Results and Provides Update on Impact of COVID-19 Pandemic Business Wire
Apr-29-20 12:34PM	Ironwood Pharmaceuticals (IRWD) Reports Next Week: Wall Street Expects Earnings Growth Zacks
Apr-28-20 04:05PM	Ironwood and Allergan Receive Notices of Allowance for Patent Applications Covering 72 mcg Dose of LINZESS® (linaclotide) Business Wire
Apr-16-20 04:05PM	Ironwood Pharmaceuticals to Host First Quarter 2020 Investor Update Call Business Wire
12:10PM	Can Ironwood (IRWD) Keep the Earnings Surprise Streak Alive? Zacks
Apr-10-20 08:49AM	An Intrinsic Calculation For Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Suggests It's 35% Undervalued Simply Wall St.
Apr-07-20 03:32PM	Hedge Funds Have Never Been This Bullish On Ironwood Pharmaceuticals, Inc. (IRWD) Insider Monkey
Mar-26-20 09:00AM	Ironwood Pharmaceuticals Provides Update on Impact of COVID-19 Business Wire
Mar-14-20 11:30AM	Ironwood (IRWD) Down 22.1% Since Last Earnings Report: Can It Rebound? Zacks
Feb-26-20 04:05PM	Ironwood Pharmaceuticals Announces Publication of Positive IW-3718 Phase IIb Data in Gastroenterology Business Wire
Feb-25-20 04:05PM	Ironwood Pharmaceuticals to Present at Upcoming March Investor Conferences Business Wire
Feb-20-20 11:13AM	Edited Transcript of IRWD earnings conference call or presentation 13-Feb-20 1:30pm GMT Thomson Reuters StreetEvents
Feb-14-20 09:50AM	Ironwood (IRWD) Surpasses Q4 Earnings and Sales Estimates Zacks -7.73%
Feb-13-20 09:45AM	Ironwood Pharmaceuticals (IRWD) Q4 Earnings and Revenues Beat Estimates Zacks
08:48AM	Ironwood (IRWD) Beats Earnings & Revenues Estimates in Q4 Zacks
07:00AM	Ironwood Pharmaceuticals Reports Strong Fourth Quarter and Full Year 2019 Results, Exceeding Full Year 2019 Guidance; Provides Full Year 2020 Guidance Business Wire
Feb-10-20 12:38PM	Does The Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Share Price Tend To Follow The Market? Simply Wall St.
10:13AM	What's in Store for Ironwood (IRWD) This Earnings Season? Zacks
Feb-06-20 12:31PM	Ironwood Pharmaceuticals (IRWD) Earnings Expected to Grow: Should You Buy? Zacks
Jan-30-20 04:05PM	Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2019 Investor Update Call Business Wire
Jan-22-20 09:20AM	Ironwood and Allergan Announce Settlement with Teva Resolving LINZESS® (linaclotide) Patent Litigation Business Wire
Jan-06-20 08:00AM	Ironwood and Allergan Announce Settlement Resolving LINZESS® (linaclotide) Patent Litigation Business Wire +6.30%
Jan-02-20 04:01PM	Ironwood Pharmaceuticals to Present at J.P. Morgan Healthcare Conference Business Wire
09:35AM	5 Reasons Why Ironwood Stock Should Be in Your Portfolio Zacks
Dec-31-19 08:58AM	MEI Pharma (MEIP) Catches Eye: Stock Jumps 8.1% Zacks
Dec-27-19 12:00PM	Are You Looking for a Top Momentum Pick? Why Ironwood Pharmaceuticals (IRWD) is a Great Choice Zacks
Dec-26-19 09:00AM	Marinus Pharmaceuticals (MRNS) Catches Eye: Stock Jumps 7.7% Zacks
Dec-25-19 11:30AM	Is Ironwood Pharmaceuticals (IRWD) Outperforming Other Medical Stocks This Year? Zacks
Dec-23-19 08:33AM	Moving Average Crossover Alert: Ironwood Pharmaceuticals Zacks
Dec-19-19 07:34PM	Heres What Hedge Funds Think About Ironwood Pharmaceuticals, Inc. (IRWD) Insider Monkey
Dec-18-19 09:23AM	Pacira's Late-Stage Study on Exparel Label Expansion Positive Zacks
Dec-13-19 08:39AM	Assertio to Divest Shingles Pain Drug to Alvogen for $127.5M Zacks
Dec-10-19 09:15AM	Some Ironwood Pharmaceuticals (NASDAQ:IRWD) Shareholders Are Down 21% Simply Wall St.
08:33AM	Turning Point (TPTX) Catches Eye: Stock Jumps 6.1% Zacks
Dec-09-19 10:20AM	Sage Therapeutics (SAGE) in Focus: Stock Moves 7.1% Higher Zacks
Dec-03-19 08:51AM	Top Ranked Momentum Stocks to Buy for December 3rd Zacks
Nov-29-19 09:39AM	Catalyst Focuses on Firdapse Label Expansion Amid Competition Zacks
Nov-27-19 08:21AM	The Zacks Analyst Blog Highlights: DexCom, Forterra, NeoPhotonics, Ironwood and Cardtronics Zacks
Nov-26-19 09:36AM	5 Best-Performing, Top-Ranked Growth Stocks of November Zacks
Nov-22-19 09:48AM	The Zacks Analyst Blog Highlights: Jounce Therapeutics, BioDelivery Sciences International, Ironwood Pharmaceuticals, Osmotica Pharmaceuticals and Select Medical Zacks
Nov-21-19 12:15PM	Healthcare Sector Outperforming: 5 Best ETFs & Stocks QTD Zacks
Nov-19-19 09:13AM	Esperion Therapeutics (ESPR) Catches Eye: Stock Jumps 10% Zacks
Nov-11-19 09:21AM	FibroGen (FGEN) Soars: Stock Adds 9.6% in Session Zacks
Nov-08-19 09:24AM	Ironwood Pharmaceuticals, Inc. (IRWD) Shares March Higher, Can It Continue? Zacks
08:00AM	Pharma Sector Tops in October: Best ETFs & Stocks Zacks
Nov-06-19 02:23PM	Edited Transcript of IRWD earnings conference call or presentation 31-Oct-19 12:30pm GMT Thomson Reuters StreetEvents
10:36AM	Jazz Pharma (JAZZ) Q3 Earnings Beat, Xyrem Drives Sales Zacks
10:20AM	Surging Earnings Estimates Signal Upside for Ironwood (IRWD) Stock Zacks
Nov-05-19 04:05PM	Ironwood Pharmaceuticals to Present at the 28th Annual Credit Suisse Healthcare Conference Business Wire
Nov-01-19 10:52AM	Ironwood (IRWD) Beats on Q3 Earnings & Revenues, Ups '19 View Zacks
Oct-31-19 09:05AM	Ironwood Pharmaceuticals (IRWD) Beats Q3 Earnings and Revenue Estimates Zacks +6.47%
07:00AM	Ironwood Pharmaceuticals Reports Third Quarter 2019 Results; Raises Full Year 2019 Guidance Business Wire
Oct-30-19 08:17AM	Ironwood spinout Cyclerion plans 30 layoffs after drug fails mid-stage trial American City Business Journals
Oct-28-19 10:23AM	Hedge Funds Ditched Ironwood Pharmaceuticals, Inc. (IRWD) At The Right Time Insider Monkey
08:00AM	Ironwood Pharmaceuticals to Highlight New Data at the American College of Gastroenterology 2019 Annual Scientific Meeting Business Wire
Oct-24-19 10:32AM	Ironwood Pharmaceuticals (IRWD) Reports Next Week: Wall Street Expects Earnings Growth Zacks
Oct-17-19 04:05PM	Ironwood Pharmaceuticals to Host Third Quarter 2019 Investor Update Call Business Wire
Oct-11-19 08:14AM	Are Investors Undervaluing Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) By 46%? Simply Wall St.
Sep-19-19 02:31PM	Ironwood Amends Linzess Agreement with AstraZeneca in China Zacks
Sep-18-19 07:39AM	The Daily Biotech Pulse: NewLink Genetics Rallies, Breakthrough Designation For Roche, IGM Biosciences Debuts Benzinga
02:00AM	Ironwood Pharmaceuticals and AstraZeneca Amend LINZESS® (linaclotide) Collaboration in China Business Wire
Sep-13-19 11:08AM	Ardelyx Gets FDA Approval for Ibsrela As IBS-C Treatment Zacks
Sep-10-19 03:18PM	Investors Can Find Big Returns with this First Profit Screen Zacks +6.08%
Sep-04-19 10:31AM	Ardelyx (ARDX) Gains on Tenapanor's Success in Pivotal Study Zacks
Aug-30-19 06:14PM	5 Health Care Stocks in Gurus' Portfolios GuruFocus.com
Aug-28-19 04:05PM	Ironwood Pharmaceuticals to Present at Upcoming September Investor Conferences Business Wire
Aug-27-19 08:05AM	Here's Why Ironwood Pharmaceuticals (NASDAQ:IRWD) Can Afford Some Debt Simply Wall St.
Aug-13-19 04:50PM	Ironwood Pharmaceuticals Announces Full Exercise of Convertible Notes Over-Allotment Business Wire
07:30AM	Ironwood Pharmaceuticals and Alnylam Pharmaceuticals Enter U.S. GI Disease Education and Promotional Agreement for Alnylams Givosiran in Acute Hepatic Porphyria (AHP) Business Wire

Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. The company markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and CONSTELLA name in the Canada and European Union; MD-7246, an oral, intestinal, non-opioid, pain-relieving agent for patients suffering from abdominal pain associated with GI diseases; and IW 3718, a gastric retentive formulation of a bile acid sequestrant, which is in Phase III clinical trials for the treatment of GERD. Ironwood Pharmaceuticals, Inc. has collaboration agreements with Allergan plc and AstraZeneca AB to develop and commercialize linaclotide for the treatment of IBS-C, CIC, and other gastrointestinal (GI) conditions in North America, China, Hong Kong, Macau, and Japan, as well as a license agreement with Astellas Pharma Inc. to develop and commercialize linaclotide for the treatment of IBS-C, CIC, and other GI conditions in Japan. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was founded in 1998 and is headquartered in Boston, Massachusetts.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
MacDonald Kelly	Chief Accounting Officer	Oct 08	Sale	10.50	22,714	238,497	95,838	Oct 13 04:03 PM
McHugh Julie	Director	Sep 08	Sale	9.77	7,950	77,672	123,107	Sep 09 06:26 PM
MacDonald Kelly	Chief Accounting Officer	Aug 17	Sale	10.14	575	5,831	118,552	Aug 19 04:01 PM
Rickard Jason	SVP, Chief Operating Officer	Aug 17	Sale	10.14	689	6,986	235,776	Aug 19 04:05 PM
OLANOFF LAWRENCE S	Director	Jun 10	Sale	10.06	11,350	114,181	68,629	Jun 12 04:32 PM
Rickard Jason	SVP, Chief Operating Officer	May 11	Sale	10.35	510	5,279	234,580	May 13 05:23 PM
MCCOURT Thomas A	President	May 11	Sale	10.35	1,697	17,564	319,847	May 13 05:22 PM
MacDonald Kelly	Chief Accounting Officer	May 11	Sale	10.35	1,153	11,934	118,147	May 13 05:20 PM
Mallon Mark	Chief Executive Officer	May 11	Sale	10.35	23,206	240,182	501,280	May 13 05:21 PM
Kilroy Conor	SVP, GC & Secretary	May 11	Sale	10.35	716	7,411	128,921	May 13 05:19 PM
Mallon Mark	Chief Executive Officer	Feb 24	Sale	11.25	1	11	303,425	Feb 25 04:45 PM
Mallon Mark	Chief Executive Officer	Feb 21	Sale	11.63	7,983	92,842	303,426	Feb 25 04:45 PM
MCCOURT Thomas A	President	Feb 21	Sale	11.63	4,177	48,579	221,062	Feb 25 04:37 PM
MacDonald Kelly	Chief Accounting Officer	Feb 21	Sale	11.63	3,900	45,357	83,127	Feb 25 04:36 PM
Gilbert Halley E	Chief Admin Officer & SVP	Feb 21	Sale	11.63	15,328	178,265	265,991	Feb 25 04:33 PM
Consylman Gina	SVP, CFO & Treasurer	Feb 21	Sale	11.63	12,501	145,387	202,787	Feb 25 04:31 PM
Gilbert Halley E	Chief Admin Officer & SVP	Jan 31	Option Exercise	10.02	60,000	601,200	341,319	Feb 04 04:02 PM
Gilbert Halley E	Chief Admin Officer & SVP	Jan 31	Sale	12.05	60,000	723,000	281,319	Feb 04 04:02 PM
MCCOURT Thomas A	President	Jan 24	Option Exercise	10.02	20,000	200,400	245,239	Jan 28 04:02 PM
MCCOURT Thomas A	President	Jan 24	Sale	12.71	20,000	254,200	225,239	Jan 28 04:02 PM
Currie Mark G	Director	Jan 23	Option Exercise	9.12	60,000	547,200	609,272	Jan 24 04:43 PM
Currie Mark G	Director	Jan 23	Sale	12.59	60,000	755,400	549,272	Jan 24 04:43 PM
Currie Mark G	Director	Jan 16	Option Exercise	10.02	8,888	89,058	558,160	Jan 21 05:23 PM
Currie Mark G	Director	Jan 16	Sale	12.80	8,888	113,766	549,272	Jan 21 05:23 PM
MacDonald Kelly	Chief Accounting Officer	Nov 08	Sale	11.00	987	10,857	78,337	Nov 12 06:26 PM
Consylman Gina	SVP, CFO & Treasurer	Nov 08	Sale	11.00	1,510	16,610	174,138	Nov 12 06:23 PM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience